Sun et al. also demonstrated that c-MYC regulates cisplatin resistance in ovarian cancer by suppressing miR-137 and promoting expression of EZH2, which in turn activates cellular survival pathways (99). The gene discussed is MYC; the disease is ovarian cancer.